

# Prof. Dr. med. Michael P. Schön

## Klinische Tätigkeit:

Allgemeine Dermatologie, Allergologie, Dermatohistologie.  
Entzündliche Hautkrankheiten (z. B. Schuppenflechte, Neurodermitis).  
Diagnostik und Therapie von Hautkrebs.

## Wissenschaftliche Schwerpunkte:

1. Adhäsion, Migration und Funktion von Lymphozyten bei Entzündungen der Haut und anderer Organe; Pathogenese der Psoriasis
2. Antiangiogene somatische Gentherapie zur Behandlung entzündlicher Hautkrankheiten
3. Entwicklung und Evaluation experimenteller Modelle für die Psoriasis (Schuppenflechte)
4. Überwindung der Therapieresistenz maligner Tumoren (besonders Melanom)
5. Wirkmechanismen kleinmolekularer TLR-(Toll-Like Rezeptor)-Agonisten bei der Tumortherapie
6. Modulation intrazellulärer Signalwege zur Verbesserung der Sensitivität maligner Tumoren gegen Chemotherapien

## Forschungsförderung:

Europäische Union, Deutsche Forschungsgemeinschaft, Deutsche  
Krebshilfe, Industrie

## Ausgewählte Publikationen:

1. Zibert JR\*, Wallbrecht K\*, Schön M, Mir LL, Jacobsen GK, Trochon-Joseph V, Bouquet C, Villadsen LS, Cadossi R, Skov L\*, Schön MP\*: Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. *J. Clin. Invest.* 121 (1), 410-421, 2011; \*equal contribution
2. Buhl T, Meynberg HC, Kaune KM, Hünecke P, Schön MP, Fuchs T: Long-term follow-up in patients with NSAID hypersensitivity reveals significant shortcomings in patients' compliance and medical care. *J. Allergy Clin. Immunol.* 127(1), 284-285, 2011
3. Hänssle HA, Richter A, Buhl T, Haas E, Holzkamp R, Emmert S, Schön MP: Induction of pigmented basal cell carcinomas after orbital radiation therapy for Graves' Ophthalmopathy. *J. Am. Acad. Dermatol.* 147(4), 511-512, 2011
4. Singh TP, Huettner B, Koefeler H, Mayer G, Wallbrecht K, Schön MP, Wolf P: Platelet-activating factor blockade inhibits Th17 pathway and suppresses psoriasis-like skin disease in K5.hTGF-beta1 transgenic mice. *Am. J. Pathol.* 178(2), 699-708, 2011
5. Thoms KM, Hellriegel S, Krone B, Beckmann I, Schön MP, Bertsch HP, Kretschmer L: Successful treatment of classic Kaposi's sarcoma with low-dose intramuscular immunoglobulins. *Br. J. Dermatol.*, in press, 2011
6. Zutt M, Krüger U, Rosenberger A, Schön MP, Neumann C, von Ahsen N, Kretschmer L: Thrombophilia in patients with chronic venous leg ulcers- a study on patients with or without postthrombotic syndrome. *J. Eur. Acad. Dermatol.*, in press, 2011
7. Boeckmann L, Nickel AC, Kuschal C, Schaefer A, Thoms KM, Schön MP, Thomale J, Emmert S: Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.. *Melanoma Res.* PMID: 21460749, 2011

8. Emmert B, Hallier E, Schön MP, Emmert S: Disease management guidelines in dermatology: Implementation, potentials and limitations exemplified by the guidelines for the management of hand eczema. *Hautarzt* in press, 2011
9. Thoms KM, Kuschal C, Oetjen E, Mori T, Kobayashi N, Laspe P, Böckmann L, Schön MP, Emmert S: Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: Implications for tumorigenesis under immunosuppression. *Exp. Dermatol.* 20(3), 232-236, 2011
10. Goppold A, Kaune KM, Buhl T, Schön MP, Zutt M: 595 nm pulsed dye laser combined with intralesional corticosteroids in hypertrophic symptomatic scars following breast reduction surgery. *Eur. J. Dermatol.*, PMID: 21382779, 2011
11. Zutt M, Krüger U, Rosenberger A, Schön MP, Neumann C, von Ahsen N, Kretschmer L: Lipoprotein (a) elevation in patients with chronic venous leg ulcers: a prospective study on patients with or without postthrombotic syndrome. *Wound Repair Regen.* 19(2), 168-172, 2011
12. Mitteldorf C, Bertsch HP, Baumgart M, Wulf C, Schön MP, Rosenwald A, Neumann C, Kaune KM: Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q. *J. Eur. Acad. Dermatol.*, in press, 2011
13. Kaune K, Neumann C, Hallermann C, Haller F, Schön MP, Middel P: Simultaneous aberrations of single CDKN2A network components and a high Rb-phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas. *Exp. Dermatol.* 20(4), 331-335, 2011
14. Wollenberg A, Bieber T, Dirschka T, Luger T, Meurer M, Proksch E, Schön MP, Schwarz T, Thaci D, Zuberbier T, Werfel T: Periorale Dermatitis (Leitlinie der Deutschen Dermatologischen Gesellschaft, Entwicklungsstufe 2), *J. Dtsch. Dermatol. Ges.* 9(5), 422-427, 2011
15. Buhl T, Hansen-Hagge C, Korpas B, Kaune KM, Rosenberger A, Schön MP, Emmert S, Hänssle HA: Integrating static and dynamic features of melanoma: The DynaMel algorithm. *J. Am. Acad. Dermatol.*, in press, 2011
16. Emmert B, Hallier E, Schön MP, Emmert S: Xeroderma pigmentosum (XP): A genetic disease sheds light on UV-induced skin cancer. *Hautarzt* 62(2), 91-97, 2011
17. Brehmer D, Schön MP: Endonasal phototherapy significantly alleviates symptoms of allergic rhinitis, but has a limited impact on the nasal mucosal immune cells. *Eur. Arch. Otorhinolaryngol.* 268(3), 393-396, 2011
18. Erpenbeck L, Schön MP: Deadly allies: the fatal interplay between platelets and metastasizing tumor cells. *Blood*, 115(17), 3427-3436, 2010
19. Singh TP, Schön MP, Wallbrecht K, Michaelis K, Rinner B, Mayer G, Schmidbauer U, Strohmeier H, Wang X-J, Wolf P: 8-methoxypsoralen therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ Tregs involving CTLA4 signaling in a psoriasis-like skin disorder. *J. Immunol.* 184(12), 7257-7267, 2010
20. Boehncke WH, Boehncke S, Schön MP: Managing comorbid disease in patients with psoriasis. *Brit. Med. J.*, Jan 15;340:b5666. doi: 10.1136/bmj.b5666, 2010
21. Amschler K\*, Schön MP\*, Pletz N, Wallbrecht K, Erpenbeck L, Schön M: NF- $\kappa$ B inhibition through proteasome inhibition or IKK $\beta$  blockade increase the susceptibility of melanoma cells to cytostatic treatment via distinct pathways. *J. Invest. Dermatol.* 130(4), 1073-1086, 2010; \*equal contribution
22. Hautz T, Zelger B, Grahammer J, Krapf C, Amberger A, Brandacher G, Landin L, Müller HG, Schön MP, Cavadas P, Lee AWP, Pratschke J, Margreiter R, Schneeberger S: Investigating molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. *Am. J. Transplant.* 10(5), 1200-1209, 2010
23. Erpenbeck L, Rubant S, Hardt K, Santoso S, Boehncke WH, Schön MP\*, Ludwig RJ\*: Constitutive and functionally relevant expression of JAM-C on platelets. *Thromb. Haemost.* 103(4), 857-859, 2010; \*equal contribution

24. Erpenbeck L, Nieswandt B, Schön M, Pozgajova M, Schön MP: Inhibition of platelet GPIIb/IIIa and promotion of melanoma metastasis. *J. Invest. Dermatol.* 130(2), 576-586, 2010
25. Jung AG, Bertsch HP, Schön MP, Lippert U: A rare case of sclerodermoid chronic graft versus host disease: Successful treatment with extracorporeal photopheresis. *Hautarzt* 61, 514-517, 2010
26. Hänssle HA, Korpas B, Hansen-Hagge C, Buhl T, Kaune KM, Rosenberger A, Krueger U, Schön MP, Emmert S: Seven-point checklist for dermoscopy: Performance during 10 years of prospective surveillance of patients at increased melanoma risk. *J. Am. Acad. Dermatol.* 62(5), 785-793, 2010
27. Kaune KM, Haas E, Schön MP, Zutt M: Multiple basal cell carcinomas arising in radiotherapy-treated naevus flammeus: early detection facilitated by 595-nm pulsed dye laser. *Eur. J. Dermatol.* 20(4), 510-511, 2010
28. Hänssle HA, Korpas B, Hansen-Hagge C, Buhl T, Kaune KM, Johnsen S, Rosenberger A, Schön MP, Emmert S: Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. *Arch. Dermatol.* 146(3), 257-264, 2010
29. Sieblist C, Wienrich BG, Schön MP, Zutt M: Ausgedehnte Lungenembolie bei Varikophlebitis. *Hautarzt* 61(11), 973-975, 2010
30. Wienrich BG, Bertsch HP, Schön MP, Emmert S: Dark grey hyperpigmentation on the face and neck. *J. Dtsch. Dermatol. Ges.* 8(7), 544-546, 2010
31. Wozel G, Sticherling M, Schön MP: Cutaneous side effects of inhibition of VEGF signal transduction. *J. Dtsch. Dermatol. Ges.* 8(4), 243-249, 2010
32. Michaelis K, Wallbrecht K, Kerstan A, Beyersdorf N, Williams C, Kerkau T, Wang XJ, Hünig T, Schön MP: Modulating T cell functions does not alleviate chronic inflammatory skin lesions in K5.TGFb1 transgenic mice. *Exp. Dermatol.* 19(5), 406-415, 2010
33. Haenssle HA, Riedl P, Buhl T, Schardt A, Rosenberger A, Schön MP, Schirmbeck R: Intracellular delivery of major histocompatibility complex class I-binding epitopes: dendritic cells loaded and matured with cationic peptide/poly(I:C) complexes efficiently activate T cells. *Exp. Dermatol.* 19(1), 19-28, 2010
34. Knudsen S, Schardt A, Buhl T, Boeckmann L, Schön MP, Neumann C, Haenssle HA: Enhanced T cell activation by immature dendritic cells loaded with HSP70-expressing heat-killed melanoma cells. *Exp. Dermatol.*, 19(2) 108-116, 2010
35. Buhl T, Wienrich BG, Sieblist C, Schön MP, Seitz CS: Development of segmental superficial actinic porokeratosis during immunosuppressive therapy for pemphigus vulgaris. *Acta Derm-Venereol.* 90(2), 212-213, 2010
36. Mousa W, Kues K, Haas E, Lauerer P, Pavlakovic H, Schön MP, Zutt M: Successful treatment of a large haemangioma in an infant by propranolol. *J. Dtsch. Dermatol. Ges.* 8(3), 184-186, 2010
37. Schön MP, Schön M: To die or not to die, that's the question – and the answer may depend on netrin-1. *J. Natl. Cancer Inst.* 101, 217-219, 2009
38. Kaune KM, Baumgart M, Gesk S, Middel P, Ghadimi BM, Siebert R, Bertsch HP, Schön MP, Neumann C: Secondary cutaneous vasculitis like MALT lymphoma with an IGL-MYC fusion. *Arch. Dermatol.* 145, 955-958, 2009
39. Haenssle HA, Kaune KM, Buhl T, Thoms KM, Padeken M, Emmert S, Schön MP: Melanoma arising in segmental nevus spilus: Early detection with sequential digital dermoscopy. *J. Am. Acad. Dermatol.* 61, 337-341, 2009
40. Buhl T, Bertsch HP, Kaune KM, Mitteldorf C, Schön MP, Kretschmer L: Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides. *Clin. Lymphoma Myeloma* 9, E21-E24, 2009

41. Boeckmann L, Schirmer M, Rosenberger A, Thoms KM, Gutzmer R, Has C, Kunz M, Kuschal C, Laspe P, Struever, Schön MP, Brockmoeller J, Emmert S: Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians. *Pharmacogenet. Genomics* 19, 760-769, 2009
42. Ludwig RJ, Hardt K, Hatting M, Bistrrian R, Diehl S, Radeke H, Podda M, Schön MP, Kaufmann R, Henschler R, Pfeilschifter J, Santoso S, Boehncke WH: Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin. *Immunology* 128(2), 196-205, 2009
43. Buhl T, Bertsch HP, Raab BW, Kaune KM, Vasko R, Strutz F, Schön MP, Lippert U: Fulminant Polyarteritis Nodosa associated with Acute Myeloid Leukemia resulted in Bilateral Lower Leg Amputation. *Rheumatology* 48, 1170-1172, 2009
44. Kaune KM, Baumgart M, Mitteldorf C, Haase D, Ghadimi BM, Bertsch HP, Schön MP, Neumann C: Solitary cutaneous nodule of CD4+/CD56+ hematodermic neoplasm progressed to overt leukaemia cutis after chemotherapy: Immunohistology and FISH analysis confirmed the diagnosis. *Am. J. Dermatopath.* 31(7), 695-701, 2009
45. Mössner R, Schön MP: Medikamentöse Systemtherapien der Psoriasis. CME-Artikel. *Akt. Dermatol.* 36, 142-152, 2009
46. Kaune K, Haas E, Emmert S, Schön MP, Zutt M: Successful treatment of severe keratosis pilaris rubra with a 595 nm pulsed dye laser. *Dermatol. Surg.* 35, 1592-1595, 2009
47. Giegold O, Ludwig RJ, Hardt K, Will J, Schön MP, Oostingh GJ, Pfeilschifter JM, Boehncke WH, Radeke HH: Computer-aided analysis of cell interactions under dynamic flow conditions. *Exp. Dermatol.* 18, 238-245, 2009
48. Alban S, Ludwig RJ, Bendas G, Schön MP, Oostingh GJ, Radeke HH, Fritzsche J, Pfeilschifter J, Kaufmann R, Boehncke WH: PS3, a semisynthetic b-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. *J. Invest. Dermatol.* 129, 1192-1202, 2009
49. Gesierich A, Stoevesandt J, Kneitz C, Bröcker EB, Schön MP: Adult-onset Still's disease – an uncommon differential diagnosis of urticaria and treatment with anakinra. *J. Eur Acad. Dermatol.* 23, 104-106, 2009
50. Schön M, Wienrich BG, Kneitz S, Schlickum S, Sennefelder H, Vöhringer V, Hüttinger-Kirchhof N, Stiewe T, Ziegelbauer K, Schön MP: KINK-1, a novel small-molecule inhibitor of IKKb, and the susceptibility of melanoma cells to antitumoral treatment. *J. Natl. Cancer Inst.* 100, 862-875, 2008
51. Schön MP, Schön M: TLR7 and TLR8 as targets in cancer therapy. *Oncogene* 27, 190-199, 2008
52. Goodman RS, Kirton CM, Oostingh GJ, Schön MP, Clark MR, Bradley JA, Taylor CJ: PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. *Transplantation* 85, 471-477, 2008
53. Papavassilis C, de Souza EM, Bröcker EB, Schön MP: Rapidly growing nodule on the ear lobe. *J. Dtsch. Dermatol. Ges.* 6, 63-64, 2008
54. Schlickum S, Sennefelder H, Friedrich M, Harms G, Lohse MJ, Kilshaw P, Schön MP: Integrin  $\alpha_E(CD103)\beta_7$  influences cellular shape and motility in a ligand-dependent fashion. *Blood* 112, 619-625, 2008
55. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schön MP, Henkler F, Wajant H, Gollnick H, Walczak H, Leverkus M: cFLIP is a critical regulator of TRAIL- or CD95-mediated apoptosis in human melanoma. *Oncogene* 27, 3211-3220, 2008
56. Wienrich BG, Schuppe HC, Schön MP: Expression and putative function of LEEP-CAM (Lymphocyte Endothelial Epithelial-Cell Adhesion Molecule) in human testis. *Andrologia* 40, 252-258, 2008
57. Schön MP: Efalizumab in the treatment of psoriasis. *Clin. Dermatol.* 26, 509-514, 2008
58. Schön MP: Animal models of psoriasis – a critical appraisal. *Exp. Dermatol.* 17, 703-712, 2008

59. Li Y, Zollner TM, Schön MP: Targeting leukocyte recruitment in the pathogenesis of psoriasis. *Clin. Dermatol.* 26, 527-538, 2008
60. Schön MP: Treatment of psoriasis: a journey from empiricism to evidence. *Clin. Dermatol.* 26, 417-418, 2008
61. Dörrie J, Schaft N, Müller I, Wellner V, Schunder T, Hänig J, Oostingh GJ, Schön MP, Robert C, Kämpgen E, Schuler G: Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. *Cancer Immunol. Immunother.* 57, 467-477, 2008
62. Seitz CS, Schön MP: Hautveränderungen bei rheumatoider Arthritis. *Arthritis und Rheuma* 28, 15-19, 2008
63. Mössner R, Schön MP, Reich K: TNF antagonists in the therapy of psoriasis. *Clin. Dermatol.* 26, 486-502, 2008
64. Oostingh GJ, Ludwig RJ, Enders S, Grüner S, Harms G, Boehncke WH, Nieswandt B, Tauber R, Schön MP: Diminished lymphocyte adhesion and alleviation of allergic responses by small-molecule- or antibody-mediated inhibition of L-selectin functions. *J. Invest. Dermatol.* 127, 90-97, 2007
65. Schön M, Schön MP: The antitumoral mode of action of imiquimod and other imidazoquinolines. *Curr. Med. Chem.* 14, 681-687, 2007
66. Merkle S, Buitrago M, Schön MP, Frantz S, Frost RJA, Schmitteckert E, Lohse MJ, Engelhardt S: A role for caspase-1 in heart failure. *Circ. Res.* 100, 645-653, 2007
67. Zollner TM, Asadullah K, Schön MP: Targeting leukocyte trafficking to the skin – Still an attractive therapeutic target? *Exp. Dermatol.* 16, 1-12, 2007
68. Kerstan A, Goebeler M, Schmidt E, Bröcker EB, Schön MP: Lupus erythematosus profundus in an 8-year-old child. *J. Eur. Acad. Dermatol.* 21, 132-133, 2007
69. Oostingh GJ, Pozgajova M, Ludwig RJ, Krahn T, Boehncke WH, Nieswandt B, Schön MP: Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. *Haematol. Hematol. J.* 92, 502-512, 2007
70. Oostingh GJ, Schlickum S, Friedl P, Schön MP: Impaired induction of adhesion molecule expression in immortalized endothelial cells leads to functional defects in dynamic interactions with lymphocytes. *J. Invest. Dermatol.* 127, 2253-2258, 2007
71. Rattenholl A, Seeliger S, Buddenkotte J, Schön M, Schön MP, Vergnolle N, Ständer S, Steinhoff M: Proteinase-activated receptor-2 (PAR2): A tumor suppressor in skin carcinogenesis. *J. Invest. Dermatol.* 127, 2245-2252, 2007
72. Schön MP, Schön M: Imiquimod – mode of action. *Br. J. Dermatol.*, 157s, 8-13, 2007
73. Schön MP: Psoriasis in the limelight – the remarkable career of an old skin disease. *Clin. Dermatol.* 25, 501-503, 2007
74. Wachter T, Murach WM, Bröcker EB, Schön MP: Recalcitrant lithium-induced psoriasis in a suicidal patient alleviated by TNF $\alpha$  inhibition. *Br. J. Dermatol.* 157, 627-629, 2007
75. Ludwig RJ, Schön MP, Boehncke WH: P-selectin – a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. *Exp. Opin. Ther. Targets* 11, 1103-1117, 2007
76. Boehncke WH, Schön MP: Animal models of psoriasis. *Clin. Dermatol.* 25, 596-605, 2007
77. Wienrich BG, Krahn T, Schön M, Rodriguez ML, Kramer B, Busemann M, Boehncke WH, Schön MP: Structure-function relation of efomycines, a family of small-molecule inhibitors of selectin functions. *J. Invest. Dermatol.* 126, 882-889, 2006.

78. Schön MP, Schön M: The small-molecule immune response modifier imiquimod – Its mode of action and clinical use in the treatment of skin cancer. *Expert Opin. Ther. Targets* 10; 69-76, 2006
79. Schön MP, Schön M, Klotz KN: The small anti-tumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and 8-independent fashion. *J. Invest. Dermatol.* 126, 1338-1347, 2006
80. Schön MP: Pathophysiologie der Psoriasis. *Akt. Dermatol.* 32, 169-175, 2006
81. Benoit S, Schön MP: Psoriasis – klinisches Spektrum, Pathogenese und neue Aspekte zur Therapie. *Therapiewoche* 3/4.06, 70-73, 2006
82. Gesierich A, Herzog S, Grunewald SM, Tappe D, Bröcker EB, Schön MP: Eosinophilic folliculitis in a Caucasian patient: Association with toxocariasis? *J. Eur. Acad. Dermatol.* 20, 1317-1321, 2006
83. Schön MP: Die Behandlung der Psoriasis. *Arzneiverordnung in der Praxis* 33. 99-101, 2006
84. Kerstan A, Schön MP: Viewpoint: Who is really in control of skin immunity under physiological circumstances –lymphocytes, dendritic cells, or keratinocytes? *Exp. Dermatol.* 15, 929, 2006
85. Schön MP: Cell adhesion molecules as therapeutic targets. *Expert Opin. Ther. Targets* 10; 799-802, 2006
86. Bong AB, Bonnekoh B, Schön MP, Gollnick H: Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa. *J. Am. Acad. Dermatol.* 52, 20-23, 2005
87. Schön MP, Boehncke WH: Psoriasis. *N. Engl. J. Med.* 352, 1899-1912, 2005
88. Schön MP, Ludwig R: Leukocyte trafficking to inflamed skin – molecular mechanisms and implications for therapeutic target molecules. *Expert Opin. Ther. Targets* 9, 225-243, 2005
89. Schön MP: Leukocyte extravasation as a target for anti-inflammatory therapy – which molecule to choose? *Exp. Dermatol.* 14, 74-76, 2005
90. Schön M, Kähne T, Gollnick H, Schön MP: Expression of gp130 in tumors and inflammatory disorders of the skin: Formal proof of its identity as CD146 (MUC18, Mel-CAM). *J. Invest. Dermatol.* 125, 353-363, 2005
91. Ludwig RJ, Zollner TM, Santoso S, Hardt K, Gille J, Baatz H, Schulze Johann P, Pfeffer J, Radeke HH, Schön MP, Kaufmann R, Boehncke WH, Podda M: Junctional adhesion molecules (JAM)-B and –C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. *J. Invest. Dermatol.* 125, 969-976, 2005
92. Schön MP: Inhibitors of selectin functions in the treatment of inflammatory skin disorders. *Ther. Clin. Risk Manag.* 1, 201-208, 2005
93. Siegmund K, Feuerer M, Siewert C, Ghani S, Haubold U, Dankof A, Krenn V, Schön MP, Scheffold A, Lowe JB, Hamann A, Syrbe U, Huehn J: Migration matters: regulatory T cell compartmentalization determines suppressive activity in vivo. *Blood* 106, 3097-3104, 2005
94. Schön MP, Boehncke WH, Bröcker EB: Psoriasis – clinical manifestations, pathogenesis and therapeutic perspectives. *Discov. Med.* 5, 253-258, 2005
95. Auth M, Wienrich BG, Bauer B, Seitz CS, Bröcker EB, Schön MP: Striate urticarial erythemas on trunk and extremities. *J. Dtsch. Dermatol. Ges.* 3, 812-814, 2005
96. Schön MP: Advances in psoriasis treatment. *Lancet* 366, 1333-1335, 2005
97. Schön MP: Cutaneous lymphocyte localization in the pathogenesis of psoriasis. *Ernst Schering Res Found Workshop* 44, 27-51, 2004

98. Bong AB, Gollnick H, Schön MP: Treatment of vitiligo with topical imiquimod. *J. Eur. Acad. Dermatol. Venereol.* 18, 741-742, 2004
99. Schön MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, Gollnick H, Schön M: Death receptor-independent induction of apoptosis in malignant melanoma by the small-molecule immune response modifier imiquimod. *J. Invest. Dermatol.* 122, 1266-1276, 2004
100. Schön MP, Schön M: Immune Modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod. *Apoptosis* 9, 291-298, 2004
101. Schön MP, Drewniok C, Boehncke WH: Targeting selectin functions in the pathogenesis of psoriasis. *Curr. Drug Targ. – Inflamm. Allerg.* 3, 163-168, 2004
102. Ambach A, Bonnekoh B, Nguyen M, Schön MP, Gollnick H: Imiquimod, a toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes *in vitro*. *Mol. Immunol.* 40, 1307-1314, 2004
103. Drewniok C, Schön M, Ulrich J, Zen Q, Telen M, Hartig R, Wieland I, Gollnick H, Schön MP: Molecular interactions of B-CAM (Basal-Cell Adhesion Molecule) and Laminin in epithelial skin cancer. *Arch. Dermatol. Res.* 296, 59-66, 2004
104. Drewniok C, Schön M, Schön MP: Basal-Cell Adhesion Molecule (B-CAM) is inversely associated with apoptosis, but plays a limited role for protection against apoptotic stimuli. *Skin Pharmacol. Physiol.* 17, 304-309, 2004
105. Ulrich J, Bonnekoh B, Schön M, Schön MP, Steinke R, Rössner A, Gollnick H: Prognostic significance of improved detection of micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies – Lessons from 306 consecutive melanoma patients. *Eur. J. Cancer* 40, 2812-2819, 2004
106. Boehncke WH, Schön MP: Interfering with leukocyte rolling – a promising therapeutic approach in inflammatory skin disorders? *Trends Pharmacol. Sci.* 24, 49-52, 2003
107. Schuppe HC, Wienrich BG, Pauls K, Schön M, Brenner MB, Schön MP: Detection of lymphocyte endothelial epithelial-Cell Adhesion Molecule (LEEP-CAM) in human testis. *Andrologia* 35, 10-11, 2003
108. Schön MP, Zollner TM, Boehncke WH: The molecular basis of lymphocyte recruitment to the skin - clues for pathogenesis and selective therapies of inflammatory disorders. *J. Invest. Dermatol.* 121, 951-962, 2003
109. Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schön MP: Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. *J. Natl. Cancer Inst.* 95, 1138-1149, 2003
110. Drewniok C, Schön MP, Krause M, Gollnick H: Secret miners pull the trigger: Scabies underlying recalcitrant Darier's disease. *J. Dtsch. Dermatol. Ges.* 1, 722-724, 2003
111. Schön MP, Boehncke WH: Efomycine: Anti-entzündliche Therapie durch Hemmung der Leukozyten-Endothelzell-Interaktion. *Akt. Dermatol.* 29, 431-434, 2003
112. Reifenberger J, Schön MP: Molekulare Grundlagen und pathogeneseorientierte Therapie epithelialer Tumoren der Haut. *Hautarzt* 54, 1164-1170, 2003
113. Schön MP, Krahn T, Schön M, Rodriguez M-L, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm K-D, Schramm M, Henninger K, Kaufmann R, Gollnick HPM, Parker CM, Boehncke W-H: Efomycine M, a novel specific selectin inhibitor, impairs leukocyte adhesion and alleviates cutaneous inflammation. *Nat. Med.* 8, 366-372, 2002
114. Schön MP, Schön M, Parker CM, Williams IR: Dendritic epidermal T cells (DETC) are diminished in  $\alpha_E$ (CD103)-deficient mice. *J. Invest. Dermatol.* 119, 190-193, 2002
115. Megahed M, Schön M, Selimovic D, Schön MP: Reliability of diagnosis of melanoma in situ. *Lancet* 359, 1921-1922, 2002

116. Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H: Imiquimod, a new immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. *Dermatology* 205, 135-138, 2002
117. Schön M, Behmenburg C, Ruzicka T, Denzer D, Schön MP: Pathogenic function of IL-1b in psoriasiform skin lesions of Flaky Skin (fsn/fsn) mice. *Clin. Exp. Immunol.* 123, 505-510, 2001
118. Schön MP, Ruzicka T: Psoriasis: The plot thickens .... *Nat. Immunol.* 2, 91, 2001
119. Rossiter H, Beissert S, Mayer C, Schön MP, Wienrich BG, Tschachler E, Kupper TS: Targeted expression of bcl-2 to murine basal keratinocytes results in paradoxical retardation of UVB and DMBA/PMA induced tumorigenesis. *Cancer Res.* 61, 3619-3626, 2001
120. Pauls K, Schön M, Kubitzka R, Homey B, Wiesenborn A, Lehmann P, Ruzicka T, Schön MP: Role of integrin  $\alpha_E$ (CD103) $\beta_7$  for tissue-specific epidermal localization of CD8<sup>+</sup> T lymphocytes. *J. Invest. Dermatol.* 117, 569-575, 2001
121. Schön M, Schön MP: Expression of B-CAM (Basal-Cell Adhesion Molecule) is associated with immature states of human keratinocytes. *J. Invest. Dermatol.* 117, 995-997, 2001
122. Schön MP, Ruzicka T, Wienecke R, Fackler I, Lehmann P: Multiple eruptive angiofibromas of the trunk. A new entity? *Arch. Dermatol.* 137, 1533-1535, 2001
123. Schön M, Denzer D, Kubitzka R, Ruzicka T, Schön MP: Critical role of neutrophils for the generation of psoriasiform skin lesions in Flaky Skin (fsn/fsn) mice. *J. Invest. Dermatol.* 114, 976-983, 2000
124. Meharra EJ, Schön MP, Hassett D, Parker CM, Havran W, Gardner H: Reduced gut intraepithelial lymphocytes in VLA-1 null mice. *Cell. Immunol.* 201, 1-5, 2000
125. Schön MP: Is psoriasis a T cell disease? Commentary. *Exp. Dermatol.* 9, 373-374, 2000
126. Schön MP, Schön M, Warren HB, Donohue JP, Parker CM: Cutaneous inflammatory disorder in integrin  $\alpha_E$  (CD103) deficient mice. *J. Immunol.* 165, 6583-6589, 2000
127. Schön M, Klein CE, Hogenkamp V, Kaufmann R, Wienrich BG, Schön MP: Basal-Cell Adhesion Molecule (B-CAM) is induced in epithelial skin tumors and inflammatory epidermis, and is expressed at cell-cell- and cell-substrate contact sites. *J. Invest. Dermatol.* 115, 1047-1053, 2000
128. Schön MP, Ruzicka T: Retinoid – ultraviolet light-combinations for the treatment of psoriasis. *Retinoids Lipid-Soluble Vit. Clin. Pract.* 16, 60-64, 2000
129. Schön MP, Heisterkamp T, Ahrens C, Megahed M, Ruzicka T: Prästernales verruköses Karzinom. *Hautarzt* 51, 766-769, 2000
130. Schön MP, Reifenberger J, Gantke B, Megahed M, Lehmann P: Progressive vernarbende Alopezie bei AIDS. *Hautarzt* 51, 935-938, 2000
131. Schön MP, Brunner M, Ruzicka T, Megahed M: Psoriasis capitis with scarring alopecia. *Cosmet. Dermatol.* 14, 29-32, 2000
132. Schön MP: Animal models of psoriasis – what can we learn from them? *J. Invest. Dermatol.* 112, 405-410, 1999
133. Schön MP, Arya A, Murphy EA, Adams CM, Strauch U, Agace WW, Her H, Olson S, LeFrancois L, Brenner MB, Grusby MJ, Parker CM: Mucosal T lymphocyte distribution is altered in integrin  $\alpha_E$ (CD103) deficient mice. *J. Immunol.* 162, 6641-6649, 1999
134. Shieh C-C, Sadasivan B, Russell GJ, Schön MP, Parker CM, Brenner MB: Lymphocyte adhesion to epithelia and endothelia mediated by the LEEP-CAM glycoprotein. *J. Immunol.* 163, 1592-1601, 1999
135. Lefrancois L, Parker CM, Olson S, Muller, Wagner N, Schön MP, Puddington L: The role of  $\beta_7$  integrins in CD8 T cell trafficking during an antiviral immune response. *J. Exp. Med.* 189, 1631-1638, 1999

136. Schön MP, Reifenberger J, von Schmiedeberg S, Megahed M, Lang K, Gattermann N, Meckenstock G, Goerz G, Ruzicka T: Multiple basal cell carcinomas associated with hairy cell leukemia. *Br. J. Dermatol.* 140, 150-153, 1999
137. Detmar M, Brown LF, Schön MP, Elicker BM, Richard L, Velasco P, Fukumura D, Monsky W, Claffey KP, Jain RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. *J. Invest. Dermatol.* 111, 1-6, 1998
138. Schön MP, Detmar M, Parker CM: Murine psoriasis-like disorder induced by naive CD4<sup>+</sup> T cells. *Nat. Med.* 3: 183-188, 1997
139. Schön MP, Parker CM: A T-cell-initiated murine model of inflammatory skin lesions. *Retinoids Lipid-Soluble Vit Clin Pract* 13, 128-131, 1997
140. Almond-Roesler B, Schön M, Schön MP, Blume-Peytavi U, Sommer C, Löster K, Orfanos CE: Cultured dermal papilla cells of the rat vibrissa follicle. Proliferative activity, adhesion properties and reorganization of the extracellular matrix in vitro. *Arch. Dermatol. Res.* 289, 698-704, 1997
141. Schön MP, Parker CM: Animal models of psoriasis (letter). *Nat. Med.* 3, 475-476, 1997
142. Schön M, Schön MP, Geilen CC, Hoffmann M, Hakyi N, Orfanos CE, Reutter W: Cell-matrix interactions of normal and transformed human keratinocytes in vitro are modulated by the synthetic phospholipid analogue hexadecylphosphocholine. *Br. J. Dermatol.* 135: 696-703, 1996
143. Schön M, Schön MP, Kuhröber A, Schirmbeck R, Kaufmann R, Klein CE: Expression of the human  $\alpha 2$  integrin subunit in mouse melanoma cells confers the ability to undergo collagen-directed adhesion, migration, and matrix-reorganization. *J. Invest. Dermatol.* 106: 1175-1181, 1996
144. Schön MP, Orfanos CE: Transformation of human keratinocytes is characterized by quantitative and qualitative alterations of the T-16 antigen (Trop-2, MOv16). *Int. J. Cancer* 60: 88-92, 1995
145. Schön MP, Blume U, Schön M, Orfanos CE: The human hair follicle: Glycoprotein-related antigenic profile of distinct keratinocytic populations in vivo and their alterations in vitro. *Arch. Dermatol. Res.* 287: 591-598, 1995
146. Schön MP, Schön M, Klein CE, Kaufmann R, Herzberg F, Schmidt R, Orfanos CE: Properties of the carcinoma-associated antigen MH99 / KS1/4 in normal and transformed human keratinocytes: Regulation of synthesis, molecular crosslinking, and ultrastructural localization. *Br. J. Dermatol.* 133: 176-185, 1995
147. Schön MP, Limat A, Hartmann B, Klein CE: Characterization of an 80 kD membrane glycoprotein of human keratinocytes: A marker for commitment to terminal differentiation in vivo and in vitro. *J. Invest. Dermatol.* 105: 418-425, 1995
148. Blume U, Schön MP, Zouboulis C, Detmar M, Orfanos CE: Vellus-hair derived keratinocyte culture: A new experimental model in human hair research. *Skin Pharmacol.* 7: 27-32, 1994
149. Schön MP, Schön M, Klein CE, Blume U, Bisson S, Orfanos CE: Carcinoma-associated 38 kD membrane glycoprotein MH99 / KS1/4 is related to proliferation and age of transformed epithelial cell lines. *J. Invest. Dermatol.* 102: 987-991, 1994
150. Schön MP, Tebbe B, Trautmann C, Orfanos CE: Lichenoid drug eruption induced by spironolactone. *Acta Derm.-Venereol.* 74: 476, 1994
151. Schön MP, Schön M, Mattes MJ, Stein R, Weber L, Alberti S, Klein CE: Biochemical and immunological characterization of the human carcinoma-associated antigen MH99 / KS1/4. *Int. J. Cancer.* 55: 988-995, 1993
152. Klein CE, Hartmann B, Schön MP, Weber L, Alberti S: Expression of a 38-kD cell surface glycoprotein in transformed human keratinocyte cell lines, basal cell carcinomas, and epithelial germs. *J. Invest. Dermatol.* 95: 74-82, 1990

# Michael P. Schön, M.D.

**Clinical spectrum:** general dermatology, allergology, dermatopathology  
chronic inflammatory disorders (e.g., psoriasis, atopic dermatitis), skin cancer (diagnosis, prevention, therapy)

**Scientific profile:**

1. Adhesion, migration and function of lymphocytes in skin inflammation; pathogenesis and therapy of psoriasis
2. anti-angiogenic gene therapy for inflammatory disorders
3. preclinical experimental models for psoriasis
4. tumor resistance against therapy (melanoma, epithelial tumors)
5. mode of action of small molecule TLR agonists in tumor therapy
6. therapeutic modulation of intracellular signaling

**Funding:** European Union, Deutsche Forschungsgemeinschaft, Wilhelm-Sander-Stiftung, Industry

## Selected publications:

1. Zibert JR\*, Wallbrecht K\*, Schön M, Mir LL, Jacobsen GK, Trochon-Joseph V, Bouquet C, Villadsen LS, Cadossi R, Skov L\*, Schön MP\*: Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. *J. Clin. Invest.* 121 (1), 410-421, 2011; \*equal contribution
2. Buhl T, Meynberg HC, Kaune KM, Hünecke P, Schön MP, Fuchs T: Long-term follow-up in patients with NSAID hypersensitivity reveals significant shortcomings in patients' compliance and medical care. *J. Allergy Clin. Immunol.* 127(1), 284-285, 2011
3. Hänssle HA, Richter A, Buhl T, Haas E, Holzkamp R, Emmert S, Schön MP: Induction of pigmented basal cell carcinomas after orbital radiation therapy for Graves' Ophthalmopathy. *J. Am. Acad. Dermatol.* 147(4), 511-512, 2011
4. Singh TP, Huettner B, Koefeler H, Mayer G, Wallbrecht K, Schön MP, Wolf P: Platelet-activating factor blockade inhibits Th17 pathway and suppresses psoriasis-like skin disease in K5.hTGF-beta1 transgenic mice. *Am. J. Pathol.* 178(2), 699-708, 2011
5. Thoms KM, Hellriegel S, Krone B, Beckmann I, Schön MP, Bertsch HP, Kretschmer L: Successful treatment of classic Kaposi's sarcoma with low-dose intramuscular immunoglobulins. *Br. J. Dermatol.*, in press, 2011
6. Zutt M, Krüger U, Rosenberger A, Schön MP, Neumann C, von Ahsen N, Kretschmer L: Thrombophilia in patients with chronic venous leg ulcers- a study on patients with or without postthrombotic syndrome. *J. Eur. Acad. Dermatol.*, in press, 2011
7. Boeckmann L, Nickel AC, Kuschal C, Schaefer A, Thoms KM, Schön MP, Thomale J, Emmert S: Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.. *Melanoma Res.* PMID: 21460749, 2011
8. Emmert B, Hallier E, Schön MP, Emmert S: Disease management guidelines in dermatology: Implementation, potentials and limitations exemplified by the guidelines for the management of hand eczema. *Hautarzt* in press, 2011
9. Thoms KM, Kuschal C, Oetjen E, Mori T, Kobayashi N, Laspe P, Böckmann L, Schön MP, Emmert S: Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: Implications for tumorigenesis under immunosuppression. *Exp. Dermatol.* 20(3), 232-236, 2011

10. Goppold A, Kaune KM, Buhl T, Schön MP, Zutt M: 595 nm pulsed dye laser combined with intralesional corticosteroids in hypertrophic symptomatic scars following breast reduction surgery. *Eur. J. Dermatol.*, PMID: 21382779, 2011
11. Zutt M, Krüger U, Rosenberger A, Schön MP, Neumann C, von Ahsen N, Kretschmer L: Lipoprotein (a) elevation in patients with chronic venous leg ulcers: a prospective study on patients with or without postthrombotic syndrome. *Wound Repair Regen.* 19(2), 168-172, 2011
12. Mitteldorf C, Bertsch HP, Baumgart M, Wulf C, Schön MP, Rosenwald A, Neumann C, Kaune KM: Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q. *J. Eur. Acad. Dermatol.*, in press, 2011
13. Kaune K, Neumann C, Hallermann C, Haller F, Schön MP, Middel P: Simultaneous aberrations of single CDKN2A network components and a high Rb-phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas. *Exp. Dermatol.* 20(4), 331-335, 2011
14. Wollenberg A, Bieber T, Dirschka T, Luger T, Meurer M, Proksch E, Schön MP, Schwarz T, Thaci D, Zuberbier T, Werfel T: Periorale Dermatitis (Leitlinie der Deutschen Dermatologischen Gesellschaft, Entwicklungsstufe 2), *J. Dtsch. Dermatol. Ges.* 9(5), 422-427, 2011
15. Buhl T, Hansen-Hagge C, Korpas B, Kaune KM, Rosenberger A, Schön MP, Emmert S, Hänsle HA: Integrating static and dynamic features of melanoma: The DynaMel algorithm. *J. Am. Acad. Dermatol.*, in press, 2011
16. Emmert B, Hallier E, Schön MP, Emmert S: Xeroderma pigmentosum (XP): A genetic disease sheds light on UV-induced skin cancer. *Hautarzt* 62(2), 91-97, 2011
17. Brehmer D, Schön MP: Endonasal phototherapy significantly alleviates symptoms of allergic rhinitis, but has a limited impact on the nasal mucosal immune cells. *Eur. Arch. Otorhinolaryngol.* 268(3), 393-396, 2011
18. Erpenbeck L, Schön MP: Deadly allies: the fatal interplay between platelets and metastasizing tumor cells. *Blood*, 115(17), 3427-3436, 2010
19. Singh TP, Schön MP, Wallbrecht K, Michaelis K, Rinner B, Mayer G, Schmidbauer U, Strohmeier H, Wang X-J, Wolf P: 8-methoxypsoralen therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3<sup>+</sup> Tregs involving CTLA4 signaling in a psoriasis-like skin disorder. *J. Immunol.* 184(12), 7257-7267, 2010
20. Boehncke WH, Boehncke S, Schön MP: Managing comorbid disease in patients with psoriasis. *Brit. Med. J.*, Jan 15;340:b5666. doi: 10.1136/bmj.b5666, 2010
21. Amschler K\*, Schön MP\*, Pletz N, Wallbrecht K, Erpenbeck L, Schön M: NF- $\kappa$ B inhibition through proteasome inhibition or IKK $\beta$  blockade increase the susceptibility of melanoma cells to cytostatic treatment *via* distinct pathways. *J. Invest. Dermatol.* 130(4), 1073-1086, 2010; \*equal contribution
22. Hautz T, Zelger B, Grahammer J, Krapf C, Amberger A, Brandacher G, Landin L, Müller HG, Schön MP, Cavadas P, Lee AWP, Pratschke J, Margreiter R, Schneeberger S: Investigating molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. *Am. J. Transplant.* 10(5), 1200-1209, 2010
23. Erpenbeck L, Rubant S, Hardt K, Santoso S, Boehncke WH, Schön MP\*, Ludwig RJ\*: Constitutive and functionally relevant expression of JAM-C on platelets. *Thromb. Haemost.* 103(4), 857-859, 2010; \*equal contribution
24. Erpenbeck L, Nieswandt B, Schön M, Pozgajova M, Schön MP: Inhibition of platelet GPIIb/IIIa and promotion of melanoma metastasis. *J. Invest. Dermatol.* 130(2), 576-586, 2010
25. Jung AG, Bertsch HP, Schön MP, Lippert U: A rare case of sclerodermoid chronic graft versus host disease: Successful treatment with extracorporeal photopheresis. *Hautarzt* 61, 514-517, 2010

26. Hänssle HA, Korpas B, Hansen-Hagge C, Buhl T, Kaune KM, Rosenberger A, Krueger U, Schön MP, Emmert S: Seven-point checklist for dermoscopy: Performance during 10 years of prospective surveillance of patients at increased melanoma risk. *J. Am. Acad. Dermatol.* 62(5), 785-793, 2010
27. Kaune KM, Haas E, Schön MP, Zutt M: Multiple basal cell carcinomas arising in radiotherapy-treated naevus flammeus: early detection facilitated by 595-nm pulsed dye laser. *Eur. J. Dermatol.* 20(4), 510-511, 2010
28. Hänssle HA, Korpas B, Hansen-Hagge C, Buhl T, Kaune KM, Johnsen S, Rosenberger A, Schön MP, Emmert S: Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. *Arch. Dermatol.* 146(3), 257-264, 2010
29. Sieblist C, Wienrich BG, Schön MP, Zutt M: Ausgedehnte Lungenembolie bei Varikophlebitis. *Hautarzt* 61(11), 973-975, 2010
30. Wienrich BG, Bertsch HP, Schön MP, Emmert S: Dark grey hyperpigmentation on the face and neck. *J. Dtsch. Dermatol. Ges.* 8(7), 544-546, 2010
31. Wozel G, Sticherling M, Schön MP: Cutaneous side effects of inhibition of VEGF signal transduction. *J. Dtsch. Dermatol. Ges.* 8(4), 243-249, 2010
32. Michaelis K, Wallbrecht K, Kerstan A, Beyersdorf N, Williams C, Kerkau T, Wang XJ, Hünig T, Schön MP: Modulating T cell functions does not alleviate chronic inflammatory skin lesions in K5.TGFb1 transgenic mice. *Exp. Dermatol.* 19(5), 406-415, 2010
33. Haenssle HA, Riedl P, Buhl T, Schardt A, Rosenberger A, Schön MP, Schirmbeck R: Intracellular delivery of major histocompatibility complex class I-binding epitopes: dendritic cells loaded and matured with cationic peptide/poly(I:C) complexes efficiently activate T cells. *Exp. Dermatol.* 19(1), 19-28, 2010
34. Knudsen S, Schardt A, Buhl T, Boeckmann L, Schön MP, Neumann C, Haenssle HA: Enhanced T cell activation by immature dendritic cells loaded with HSP70-expressing heat-killed melanoma cells. *Exp. Dermatol.*, 19(2) 108-116, 2010
35. Buhl T, Wienrich BG, Sieblist C, Schön MP, Seitz CS: Development of segmental superficial actinic porokeratosis during immunosuppressive therapy for pemphigus vulgaris. *Acta Derm-Venereol.* 90(2), 212-213, 2010
36. Mousa W, Kues K, Haas E, Lauerer P, Pavlakovic H, Schön MP, Zutt M: Successful treatment of a large haemangioma in an infant by propranolol. *J. Dtsch. Dermatol. Ges.* 8(3), 184-186, 2010
37. Schön MP, Schön M: To die or not to die, that's the question – and the answer may depend on netrin-1. *J. Natl. Cancer Inst.* 101, 217-219, 2009
38. Kaune KM, Baumgart M, Gesk S, Middel P, Ghadimi BM, Siebert R, Bertsch HP, Schön MP, Neumann C: Secondary cutaneous vasculitis like MALT lymphoma with an IGL-MYC fusion. *Arch. Dermatol.* 145, 955-958, 2009
39. Haenssle HA, Kaune KM, Buhl T, Thoms KM, Padeken M, Emmert S, Schön MP: Melanoma arising in segmental nevus spilus: Early detection with sequential digital dermoscopy. *J. Am. Acad. Dermatol.* 61, 337-341, 2009
40. Buhl T, Bertsch HP, Kaune KM, Mitteldorf C, Schön MP, Kretschmer L: Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides. *Clin. Lymphoma Myeloma* 9, E21-E24, 2009
41. Boeckmann L, Schirmer M, Rosenberger A, Thoms KM, Gutzmer R, Has C, Kunz M, Kuschal C, Laspe P, Struever, Schön MP, Brockmoeller J, Emmert S: Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians. *Pharmacogenet. Genomics* 19, 760-769, 2009
42. Ludwig RJ, Hardt K, Hatting, M, Bistrrian R, Diehl S, Radeke H, Podda M, Schön MP, Kaufmann R, Henschler R, Pfeilschifter J, Santoso S, Boehncke WH: Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin. *Immunology* 128(2), 196-205, 2009

43. Buhl T, Bertsch HP, Raab BW, Kaune KM, Vasko R, Strutz F, Schön MP, Lippert U: Fulminant Polyarteritis Nodosa associated with Acute Myeloid Leukemia resulted in Bilateral Lower Leg Amputation. *Rheumatology* 48, 1170-1172, 2009
44. Kaune KM, Baumgart M, Mitteldorf C, Haase D, Ghadimi BM, Bertsch HP, Schön MP, Neumann C: Solitary cutaneous nodule of CD4+/CD56+ hematodermic neoplasm progressed to overt leukaemia cutis after chemotherapy: Immunohistology and FISH analysis confirmed the diagnosis. *Am. J. Dermatopath.* 31(7), 695-701, 2009
45. Mössner R, Schön MP: Medikamentöse Systemtherapien der Psoriasis. CME-Artikel. *Akt. Dermatol.* 36, 142-152, 2009
46. Kaune K, Haas E, Emmert S, Schön MP, Zutt M: Successful treatment of severe keratosis pilaris rubra with a 595 nm pulsed dye laser. *Dermatol. Surg.* 35, 1592-1595, 2009
47. Giegold O, Ludwig RJ, Hardt K, Will J, Schön MP, Oostingh GJ, Pfeilschifter JM, Boehncke WH, Radeke HH: Computer-aided analysis of cell interactions under dynamic flow conditions. *Exp. Dermatol.* 18, 238-245, 2009
48. Alban S, Ludwig RJ, Bendas G, Schön MP, Oostingh GJ, Radeke HH, Fritzsche J, Pfeilschifter J, Kaufmann R, Boehncke WH: PS3, a semisynthetic b-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. *J. Invest. Dermatol.* 129, 1192-1202, 2009
49. Gesierich A, Stoevesandt J, Kneitz C, Bröcker EB, Schön MP: Adult-onset Still's disease – an uncommon differential diagnosis of urticaria and treatment with anakinra. *J. Eur Acad. Dermatol.* 23, 104-106, 2009
50. Schön M, Wienrich BG, Kneitz S, Schlickum S, Sennefelder H, Vöhringer V, Hüttinger-Kirchhof N, Stiewe T, Ziegelbauer K, Schön MP: KINK-1, a novel small-molecule inhibitor of IKKb, and the susceptibility of melanoma cells to antitumoral treatment. *J. Natl. Cancer Inst.* 100, 862-875, 2008
51. Schön MP, Schön M: TLR7 and TLR8 as targets in cancer therapy. *Oncogene* 27, 190-199, 2008
52. Goodman RS, Kirton CM, Oostingh GJ, Schön MP, Clark MR, Bradley JA, Taylor CJ: PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. *Transplantation* 85, 471-477, 2008
53. Papavassilis C, de Souza EM, Bröcker EB, Schön MP: Rapidly growing nodule on the ear lobe. *J. Dtsch. Dermatol. Ges.* 6, 63-64, 2008
54. Schlickum S, Sennefelder H, Friedrich M, Harms G, Lohse MJ, Kilshaw P, Schön MP: Integrin  $\alpha_E(CD103)\beta_7$  influences cellular shape and motility in a ligand-dependent fashion. *Blood* 112, 619-625, 2008
55. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schön MP, Henkler F, Wajant H, Gollnick H, Walczak H, Leverkus M: cFLIP is a critical regulator of TRAIL- or CD95-mediated apoptosis in human melanoma. *Oncogene* 27, 3211-3220, 2008
56. Wienrich BG, Schuppe HC, Schön MP: Expression and putative function of LEEP-CAM (Lymphocyte Endothelial Epithelial-Cell Adhesion Molecule) in human testis. *Andrologia* 40, 252-258, 2008
57. Schön MP: Efalizumab in the treatment of psoriasis. *Clin. Dermatol.* 26, 509-514, 2008
58. Schön MP: Animal models of psoriasis – a critical appraisal. *Exp. Dermatol.* 17, 703-712, 2008
59. Li Y, Zollner TM, Schön MP: Targeting leukocyte recruitment in the pathogenesis of psoriasis. *Clin. Dermatol.* 26, 527-538, 2008
60. Schön MP: Treatment of psoriasis: a journey from empiricism to evidence. *Clin. Dermatol.* 26, 417-418, 2008

61. Dörrie J, Schaft N, Müller I, Wellner V, Schunder T, Hänig J, Oostingh GJ, Schön MP, Robert C, Kämpgen E, Schuler G: Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. *Cancer Immunol. Immunother.* 57, 467-477, 2008
62. Seitz CS, Schön MP: Hautveränderungen bei rheumatoider Arthritis. *Arthritis und Rheuma* 28, 15-19, 2008
63. Mössner R, Schön MP, Reich K: TNF antagonists in the therapy of psoriasis. *Clin. Dermatol.* 26, 486-502, 2008
64. Oostingh GJ, Ludwig RJ, Enders S, Grüner S, Harms G, Boehncke WH, Nieswandt B, Tauber R, Schön MP: Diminished lymphocyte adhesion and alleviation of allergic responses by small-molecule- or antibody-mediated inhibition of L-selectin functions. *J. Invest. Dermatol.* 127, 90-97, 2007
65. Schön M, Schön MP: The antitumoral mode of action of imiquimod and other imidazoquinolines. *Curr. Med. Chem.* 14, 681-687, 2007
66. Merkle S, Buitrago M, Schön MP, Frantz S, Frost RJA, Schmitteckert E, Lohse MJ, Engelhardt S: A role for caspase-1 in heart failure. *Circ. Res.* 100, 645-653, 2007
67. Zollner TM, Asadullah K, Schön MP: Targeting leukocyte trafficking to the skin – Still an attractive therapeutic target? *Exp. Dermatol.* 16, 1-12, 2007
68. Kerstan A, Goebeler M, Schmidt E, Bröcker EB, Schön MP: Lupus erythematosus profundus in an 8-year-old child. *J. Eur. Acad. Dermatol.* 21, 132-133, 2007
69. Oostingh GJ, Pozgajova M, Ludwig RJ, Krahn T, Boehncke WH, Nieswandt B, Schön MP: Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. *Haematol. Hematol. J.* 92, 502-512, 2007
70. Oostingh GJ, Schlickum S, Friedl P, Schön MP: Impaired induction of adhesion molecule expression in immortalized endothelial cells leads to functional defects in dynamic interactions with lymphocytes. *J. Invest. Dermatol.* 127, 2253-2258, 2007
71. Rattenholl A, Seeliger S, Buddenkotte J, Schön M, Schön MP, Vergnolle N, Ständer S, Steinhoff M: Proteinase-activated receptor-2 (PAR2): A tumor suppressor in skin carcinogenesis. *J. Invest. Dermatol.* 127, 2245-2252, 2007
72. Schön MP, Schön M: Imiquimod – mode of action. *Br. J. Dermatol.*, 157s, 8-13, 2007
73. Schön MP: Psoriasis in the limelight – the remarkable career of an old skin disease. *Clin. Dermatol.* 25, 501-503, 2007
74. Wachter T, Murach WM, Bröcker EB, Schön MP: Recalcitrant lithium-induced psoriasis in a suicidal patient alleviated by TNF $\alpha$  inhibition. *Br. J. Dermatol.* 157, 627-629, 2007
75. Ludwig RJ, Schön MP, Boehncke WH: P-selectin – a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. *Exp. Opin. Ther. Targets* 11, 1103-1117, 2007
76. Boehncke WH, Schön MP: Animal models of psoriasis. *Clin. Dermatol.* 25, 596-605, 2007
77. Wienrich BG, Krahn T, Schön M, Rodriguez ML, Kramer B, Busemann M, Boehncke WH, Schön MP: Structure-function relation of efomycines, a family of small-molecule inhibitors of selectin functions. *J. Invest. Dermatol.* 126, 882-889, 2006.
78. Schön MP, Schön M: The small-molecule immune response modifier imiquimod – Its mode of action and clinical use in the treatment of skin cancer. *Expert Opin. Ther. Targets* 10; 69-76, 2006
79. Schön MP, Schön M, Klotz KN: The small anti-tumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and 8-independent fashion. *J. Invest. Dermatol.* 126, 1338-1347, 2006

80. Schön MP: Pathophysiologie der Psoriasis. *Akt. Dermatol.* 32, 169-175, 2006
81. Benoit S, Schön MP: Psoriasis – klinisches Spektrum, Pathogenese und neue Aspekte zur Therapie. *Therapiewoche* 3/4.06, 70-73, 2006
82. Gesierich A, Herzog S, Grunewald SM, Tappe D, Bröcker EB, Schön MP: Eosinophilic folliculitis in a Caucasian patient: Association with toxocarasis? *J. Eur. Acad. Dermatol.* 20, 1317-1321, 2006
83. Schön MP: Die Behandlung der Psoriasis. *Arzneiverordnung in der Praxis* 33. 99-101, 2006
84. Kerstan A, Schön MP: Viewpoint: Who is really in control of skin immunity under physiological circumstances —lymphocytes, dendritic cells, or keratinocytes? *Exp. Dermatol.* 15, 929, 2006
85. Schön MP: Cell adhesion molecules as therapeutic targets. *Expert Opin. Ther. Targets* 10; 799-802, 2006
86. Bong AB, Bonnekoh B, Schön MP, Gollnick H: Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa. *J. Am. Acad. Dermatol.* 52, 20-23, 2005
87. Schön MP, Boehncke WH: Psoriasis. *N. Engl. J. Med.* 352, 1899-1912, 2005
88. Schön MP, Ludwig R: Leukocyte trafficking to inflamed skin – molecular mechanisms and implications for therapeutic target molecules. *Expert Opin. Ther. Targets* 9, 225-243, 2005
89. Schön MP: Leukocyte extravasation as a target for anti-inflammatory therapy – which molecule to choose? *Exp. Dermatol.* 14, 74-76, 2005
90. Schön M, Kähne T, Gollnick H, Schön MP: Expression of gp130 in tumors and inflammatory disorders of the skin: Formal proof of its identity as CD146 (MUC18, Mel-CAM). *J. Invest. Dermatol.* 125, 353-363, 2005
91. Ludwig RJ, Zollner TM, Santoso S, Hardt K, Gille J, Baatz H, Schulze Johann P, Pfeffer J, Radeke HH, Schön MP, Kaufmann R, Boehncke WH, Podda M: Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. *J. Invest. Dermatol.* 125, 969-976, 2005
92. Schön MP: Inhibitors of selectin functions in the treatment of inflammatory skin disorders. *Ther. Clin. Risk Manag.* 1, 201-208, 2005
93. Siegmund K, Feuerer M, Siewert C, Ghani S, Haubold U, Dankof A, Krenn V, Schön MP, Scheffold A, Lowe JB, Hamann A, Syrbe U, Huehn J: Migration matters: regulatory T cell compartmentalization determines suppressive activity in vivo. *Blood* 106, 3097-3104, 2005
94. Schön MP, Boehncke WH, Bröcker EB: Psoriasis – clinical manifestations, pathogenesis and therapeutic perspectives. *Discov. Med.* 5, 253-258, 2005
95. Auth M, Wienrich BG, Bauer B, Seitz CS, Bröcker EB, Schön MP: Striate urticarial erythemas on trunk and extremities. *J. Dtsch. Dermatol. Ges.* 3, 812-814, 2005
96. Schön MP: Advances in psoriasis treatment. *Lancet* 366, 1333-1335, 2005
97. Schön MP: Cutaneous lymphocyte localization in the pathogenesis of psoriasis. *Ernst Schering Res Found Workshop* 44, 27-51, 2004
98. Bong AB, Gollnick H, Schön MP: Treatment of vitiligo with topical imiquimod. *J. Eur. Acad. Dermatol. Venereol.* 18, 741-742, 2004
99. Schön MP, Wienrich BG, Drewniak C, Bong AB, Eberle J, Geilen CC, Gollnick H, Schön M: Death receptor-independent induction of apoptosis in malignant melanoma by the small-molecule immune response modifier imiquimod. *J. Invest. Dermatol.* 122, 1266-1276, 2004

100. Schön MP, Schön M: Immune Modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod. *Apoptosis* 9, 291-298, 2004
101. Schön MP, Drewniok C, Boehncke WH: Targeting selectin functions in the pathogenesis of psoriasis. *Curr. Drug Targ. – Inflamm. Allerg.* 3, 163-168, 2004
102. Ambach A, Bonnekoh B, Nguyen M, Schön MP, Gollnick H: Imiquimod, a toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes *in vitro*. *Mol. Immunol.* 40, 1307-1314, 2004
103. Drewniok C, Schön M, Ulrich J, Zen Q, Telen M, Hartig R, Wieland I, Gollnick H, Schön MP: Molecular interactions of B-CAM (Basal-Cell Adhesion Molecule) and Laminin in epithelial skin cancer. *Arch. Dermatol. Res.* 296, 59-66, 2004
104. Drewniok C, Schön M, Schön MP: Basal-Cell Adhesion Molecule (B-CAM) is inversely associated with apoptosis, but plays a limited role for protection against apoptotic stimuli. *Skin Pharmacol. Physiol.* 17, 304-309, 2004
105. Ulrich J, Bonnekoh B, Schön M, Schön MP, Steinke R, Rössner A, Gollnick H: Prognostic significance of improved detection of micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies – Lessons from 306 consecutive melanoma patients. *Eur. J. Cancer* 40, 2812-2819, 2004
106. Boehncke WH, Schön MP: Interfering with leukocyte rolling – a promising therapeutic approach in inflammatory skin disorders? *Trends Pharmacol. Sci.* 24, 49-52, 2003
107. Schuppe HC, Wienrich BG, Pauls K, Schön M, Brenner MB, Schön MP: Detection of lymphocyte endothelial epithelial-Cell Adhesion Molecule (LEEP-CAM) in human testis. *Andrologia* 35, 10-11, 2003
108. Schön MP, Zollner TM, Boehncke WH: The molecular basis of lymphocyte recruitment to the skin - clues for pathogenesis and selective therapies of inflammatory disorders. *J. Invest. Dermatol.* 121, 951-962, 2003
109. Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schön MP: Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. *J. Natl. Cancer Inst.* 95, 1138-1149, 2003
110. Drewniok C, Schön MP, Krause M, Gollnick H: Secret miners pull the trigger: Scabies underlying recalcitrant Darier's disease. *J. Dtsch. Dermatol. Ges.* 1, 722-724, 2003
111. Schön MP, Boehncke WH: Efomycine: Anti-entzündliche Therapie durch Hemmung der Leukozyten-Endothelzell-Interaktion. *Akt. Dermatol.* 29, 431-434, 2003
112. Reifenberger J, Schön MP: Molekulare Grundlagen und pathogeneseorientierte Therapie epithelialer Tumoren der Haut. *Hautarzt* 54, 1164-1170, 2003
113. Schön MP, Krahn T, Schön M, Rodriguez M-L, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm K-D, Schramm M, Henninger K, Kaufmann R, Gollnick HPM, Parker CM, Boehncke W-H: Efomycine M, a novel specific selectin inhibitor, impairs leukocyte adhesion and alleviates cutaneous inflammation. *Nat. Med.* 8, 366-372, 2002
114. Schön MP, Schön M, Parker CM, Williams IR: Dendritic epidermal T cells (DETC) are diminished in  $\alpha_E$ (CD103)-deficient mice. *J. Invest. Dermatol.* 119, 190-193, 2002
115. Megahed M, Schön M, Selimovic D, Schön MP: Reliability of diagnosis of melanoma in situ. *Lancet* 359, 1921-1922, 2002
116. Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H: Imiquimod, a new immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. *Dermatology* 205, 135-138, 2002
117. Schön M, Behmenburg C, Ruzicka T, Denzer D, Schön MP: Pathogenic function of IL-1b in psoriasiform skin lesions of Flaky Skin (fsn/fsn) mice. *Clin. Exp. Immunol.* 123, 505-510, 2001
118. Schön MP, Ruzicka T: Psoriasis: The plot thickens .... *Nat. Immunol.* 2, 91, 2001

119. Rossiter H, Beissert S, Mayer C, Schön MP, Wienrich BG, Tschachler E, Kupper TS: Targeted expression of bcl-2 to murine basal keratinocytes results in paradoxical retardation of UVB and DMBA/PMA induced tumorigenesis. *Cancer Res.* 61, 3619-3626, 2001
120. Pauls K, Schön M, Kubitzka R, Homey B, Wiesenborn A, Lehmann P, Ruzicka T, Schön MP: Role of integrin  $\alpha_E(\text{CD}103)\beta_7$  for tissue-specific epidermal localization of  $\text{CD}8^+$  T lymphocytes. *J. Invest. Dermatol.* 117, 569-575, 2001
121. Schön M, Schön MP: Expression of B-CAM (Basal-Cell Adhesion Molecule) is associated with immature states of human keratinocytes. *J. Invest. Dermatol.* 117, 995-997, 2001
122. Schön MP, Ruzicka T, Wienecke R, Fackler I, Lehmann P: Multiple eruptive angiofibromas of the trunk. A new entity? *Arch. Dermatol.* 137, 1533-1535, 2001
123. Schön M, Denzer D, Kubitzka R, Ruzicka T, Schön MP: Critical role of neutrophils for the generation of psoriasiform skin lesions in Flaky Skin (*fsn/fsn*) mice. *J. Invest. Dermatol.* 114, 976-983, 2000
124. Meharra EJ, Schön MP, Hassett D, Parker CM, Havran W, Gardner H: Reduced gut intraepithelial lymphocytes in VLA-1 null mice. *Cell. Immunol.* 201, 1-5, 2000
125. Schön MP: Is psoriasis a T cell disease? Commentary. *Exp. Dermatol.* 9, 373-374, 2000
126. Schön MP, Schön M, Warren HB, Donohue JP, Parker CM: Cutaneous inflammatory disorder in integrin  $\alpha_E(\text{CD}103)$  deficient mice. *J. Immunol.* 165, 6583-6589, 2000
127. Schön M, Klein CE, Hogenkamp V, Kaufmann R, Wienrich BG, Schön MP: Basal-Cell Adhesion Molecule (B-CAM) is induced in epithelial skin tumors and inflammatory epidermis, and is expressed at cell-cell- and cell-substrate contact sites. *J. Invest. Dermatol.* 115, 1047-1053, 2000
128. Schön MP, Ruzicka T: Retinoid – ultraviolet light-combinations for the treatment of psoriasis. *Retinoids Lipid-Soluble Vit. Clin. Pract.* 16, 60-64, 2000
129. Schön MP, Heisterkamp T, Ahrens C, Megahed M, Ruzicka T: Prästernales verruköses Karzinom. *Hautarzt* 51, 766-769, 2000
130. Schön MP, Reifenberger J, Gantke B, Megahed M, Lehmann P: Progressive vernarbende Alopezie bei AIDS. *Hautarzt* 51, 935-938, 2000
131. Schön MP, Brunner M, Ruzicka T, Megahed M: Psoriasis capitis with scarring alopecia. *Cosmet. Dermatol.* 14, 29-32, 2000
132. Schön MP: Animal models of psoriasis – what can we learn from them? *J. Invest. Dermatol.* 112, 405-410, 1999
133. Schön MP, Arya A, Murphy EA, Adams CM, Strauch U, Agace WW, Her H, Olson S, LeFrancois L, Brenner MB, Grusby MJ, Parker CM: Mucosal T lymphocyte distribution is altered in integrin  $\alpha_E(\text{CD}103)$  deficient mice. *J. Immunol.* 162, 6641-6649, 1999
134. Shieh C-C, Sadasivan B, Russell GJ, Schön MP, Parker CM, Brenner MB: Lymphocyte adhesion to epithelia and endothelia mediated by the LEEP-CAM glycoprotein. *J. Immunol.* 163, 1592-1601, 1999
135. Lefrancois L, Parker CM, Olson S, Muller, Wagner N, Schön MP, Puddington L: The role of  $\beta_7$  integrins in  $\text{CD}8$  T cell trafficking during an antiviral immune response. *J. Exp. Med.* 189, 1631-1638, 1999
136. Schön MP, Reifenberger J, von Schmiedeberg S, Megahed M, Lang K, Gattermann N, Meckenstock G, Goerz G, Ruzicka T: Multiple basal cell carcinomas associated with hairy cell leukemia. *Br. J. Dermatol.* 140, 150-153, 1999
137. Detmar M, Brown LF, Schön MP, Elicker BM, Richard L, Velasco P, Fukumura D, Monsky W, Claffey KP, Jain RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. *J. Invest. Dermatol.* 111, 1-6, 1998

138. Schön MP, Detmar M, Parker CM: Murine psoriasis-like disorder induced by naive CD4<sup>+</sup> T cells. *Nat. Med.* 3: 183-188, 1997
139. Schön MP, Parker CM: A T-cell-initiated murine model of inflammatory skin lesions. *Retinoids Lipid-Soluble Vit Clin Pract* 13, 128-131, 1997
140. Almond-Roesler B, Schön M, Schön MP, Blume-Peytavi U, Sommer C, Löster K, Orfanos CE: Cultured dermal papilla cells of the rat vibrissa follicle. Proliferative activity, adhesion properties and reorganization of the extracellular matrix in vitro. *Arch. Dermatol. Res.* 289, 698-704, 1997
141. Schön MP, Parker CM: Animal models of psoriasis (letter). *Nat. Med.* 3, 475-476, 1997
142. Schön M, Schön MP, Geilen CC, Hoffmann M, Hakyi N, Orfanos CE, Reutter W: Cell-matrix interactions of normal and transformed human keratinocytes in vitro are modulated by the synthetic phospholipid analogue hexadecylphosphocholine. *Br. J. Dermatol.* 135: 696-703, 1996
143. Schön M, Schön MP, Kuhröber A, Schirmbeck R, Kaufmann R, Klein CE: Expression of the human  $\alpha 2$  integrin subunit in mouse melanoma cells confers the ability to undergo collagen-directed adhesion, migration, and matrix-reorganization. *J. Invest. Dermatol.* 106: 1175-1181, 1996
144. Schön MP, Orfanos CE: Transformation of human keratinocytes is characterized by quantitative and qualitative alterations of the T-16 antigen (Trop-2, MOv16). *Int. J. Cancer* 60: 88-92, 1995
145. Schön MP, Blume U, Schön M, Orfanos CE: The human hair follicle: Glycoprotein-related antigenic profile of distinct keratinocytic populations in vivo and their alterations in vitro. *Arch. Dermatol. Res.* 287: 591-598, 1995
146. Schön MP, Schön M, Klein CE, Kaufmann R, Herzberg F, Schmidt R, Orfanos CE: Properties of the carcinoma-associated antigen MH99 / KS1/4 in normal and transformed human keratinocytes: Regulation of synthesis, molecular crosslinking, and ultrastructural localization. *Br. J. Dermatol.* 133: 176-185, 1995
147. Schön MP, Limat A, Hartmann B, Klein CE: Characterization of an 80 kD membrane glycoprotein of human keratinocytes: A marker for commitment to terminal differentiation in vivo and in vitro. *J. Invest. Dermatol.* 105: 418-425, 1995
148. Blume U, Schön MP, Zouboulis C, Detmar M, Orfanos CE: Vellus-hair derived keratinocyte culture: A new experimental model in human hair research. *Skin Pharmacol.* 7: 27-32, 1994
149. Schön MP, Schön M, Klein CE, Blume U, Bisson S, Orfanos CE: Carcinoma-associated 38 kD membrane glycoprotein MH99 / KS1/4 is related to proliferation and age of transformed epithelial cell lines. *J. Invest. Dermatol.* 102: 987-991, 1994
150. Schön MP, Tebbe B, Trautmann C, Orfanos CE: Lichenoid drug eruption induced by spironolactone. *Acta Derm.-Venereol.* 74: 476, 1994
151. Schön MP, Schön M, Mattes MJ, Stein R, Weber L, Alberti S, Klein CE: Biochemical and immunological characterization of the human carcinoma-associated antigen MH99 / KS1/4. *Int. J. Cancer.* 55: 988-995, 1993
152. Klein CE, Hartmann B, Schön MP, Weber L, Alberti S: Expression of a 38-kD cell surface glycoprotein in transformed human keratinocyte cell lines, basal cell carcinomas, and epithelial germs. *J. Invest. Dermatol.* 95: 74-82, 1990